Benuvia Operations News and Resources

Benuvia Operations, LLC, a U.S.-based global CDMO and API supplier, today announced it has entered a multi-year supply agreement with a leading U.S. pharmaceutical company. Under the terms, Benuvia will deliver its Dronabinol API to support the customer’s product development

Benuvia Operations, LLC has secured a five-year contract from the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), to manufacture psilocybin and other bulk drug substances under Good Manufacturing Practice (GMP) conditions. The contract

Benuvia Operations, LLC has been awarded Good Manufacturing Practices (GMP) certification (Certificado de Boas Práticas de Fabricação or CBPF) from Brazil’s National Health Surveillance Agency (ANVISA). This certification allows the company to manufacture and distribute non-sterile liquid pharmaceutical products in Brazil,

Benuvia Operations, LLC, a global CDMO, has announced a licensing partnership with Avernus Pharma, granting Avernus exclusive distribution rights for SYNDROS in the Gulf Cooperation Council (GCC) region. This encompasses Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE, pending

Benuvia Operations, a global contract development and manufacturing organisation (CDMO), has announced a new collaboration with Medra Brasil Medicamentos LTDA. The agreement grants Medra Brasil exclusive rights to distribute SYNDROS (dronabinol) in Brazil upon approval from the Brazilian Health Regulatory

Benuvia Operations, LLC, a company specialising in the development and manufacturing of cannabinoid, psychedelic, and controlled substance products, has announced the appointment of Terry Novak as its new Chief Executive Officer. Terry Novak, with 30 years of executive leadership experience,